Skip to main content
Top
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis

Authors: Li-Hong Wang, Xu Wang, Wen-Ting Xu, Ya-Li Hu

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Case–control studies on the association between mouse double minute 2 homolog (MDM2) rs2279744 polymorphism and endometrial cancer have provided either controversial or inconclusive results. To clarify the effect of MDM2 rs2279744 polymorphism on the risk of endometrial cancer, a meta-analysis of all case–control observational studies was performed. Pooled odds ratios (ORs) for various polymorphisms were estimated using random and fixed effect models. Q-statistic was used to evaluate the homogeneity, and Egger and Begg tests were used to assess publication bias. Overall, the MDM2 rs2279744 polymorphism was associated with a risk of endometrial cancer (OR = 0.76; 95 % CI = 0.64–0.90 for allele contrast, p = 0.002, P het = 0.003). The contrast of homozygotes and the recessive and dominant models produced the same pattern of results as the allele contrast. In the analysis stratified by ethnicity, significant associations were found in the Caucasian population in all of the genetic models. Our pooled data suggest evidence for a major role of MDM2 rs2279744 polymorphism in the carcinogenesis of endometrial cancer, especially among Caucasian populations.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69–90. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69–90.
2.
go back to reference Zhou X, Gu Y, Wang DN, Ni S, Yan J. Eight functional polymorphisms in the estrogen receptor 1 gene and endometrial cancer risk: a meta-analysis. PLoS One. 2013;8(4):e60851.PubMedCentralPubMedCrossRef Zhou X, Gu Y, Wang DN, Ni S, Yan J. Eight functional polymorphisms in the estrogen receptor 1 gene and endometrial cancer risk: a meta-analysis. PLoS One. 2013;8(4):e60851.PubMedCentralPubMedCrossRef
3.
go back to reference Wang Y, Cui M, Zheng L. Genetic polymorphisms in the estrogen receptor-α gene and the risk of endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand. 2012;91(8):911–6.PubMedCrossRef Wang Y, Cui M, Zheng L. Genetic polymorphisms in the estrogen receptor-α gene and the risk of endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand. 2012;91(8):911–6.PubMedCrossRef
4.
go back to reference Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.PubMedCrossRef Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.PubMedCrossRef
5.
go back to reference Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 2009;113(1):109–14.PubMedCrossRef Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 2009;113(1):109–14.PubMedCrossRef
6.
go back to reference Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC. MoMaTEC study group, et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer. 2012;48(13):1988–96.PubMedCrossRef Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC. MoMaTEC study group, et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer. 2012;48(13):1988–96.PubMedCrossRef
7.
go back to reference Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22(4):101–6.PubMedCrossRef Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22(4):101–6.PubMedCrossRef
8.
go back to reference Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(4):983–6.PubMedCentralPubMedCrossRef Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(4):983–6.PubMedCentralPubMedCrossRef
9.
go back to reference Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49–54.PubMedCrossRef Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49–54.PubMedCrossRef
10.
go back to reference Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007;104(3):660–4.PubMedCrossRef Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007;104(3):660–4.PubMedCrossRef
11.
go back to reference Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 2013;30(1):25–34.PubMedCentralPubMed Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 2013;30(1):25–34.PubMedCentralPubMed
12.
go back to reference Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J, Smolarz B. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol. 2012;63(4):278–83.PubMedCrossRef Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J, Smolarz B. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol. 2012;63(4):278–83.PubMedCrossRef
13.
14.
go back to reference Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
16.
go back to reference Li Y, Zhao H, Sun L, Huang L, Yang Q, Kong B. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 2011;24(2):57–64.PubMedCrossRef Li Y, Zhao H, Sun L, Huang L, Yang Q, Kong B. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 2011;24(2):57–64.PubMedCrossRef
Metadata
Title
MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis
Authors
Li-Hong Wang
Xu Wang
Wen-Ting Xu
Ya-Li Hu
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1413-8

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine